Proficio Capital Partners LLC Acquires New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Proficio Capital Partners LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 38,669 shares of the specialty pharmaceutical company's stock, valued at approximately $4,762,000. Proficio Capital Partners LLC owned about 0.06% of Jazz Pharmaceuticals as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Oppenheimer Asset Management Inc. boosted its stake in Jazz Pharmaceuticals by 24.2% in the 4th quarter. Oppenheimer Asset Management Inc. now owns 9,588 shares of the specialty pharmaceutical company's stock worth $1,181,000 after buying an additional 1,867 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Jazz Pharmaceuticals by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 477,751 shares of the specialty pharmaceutical company's stock worth $58,835,000 after acquiring an additional 24,481 shares during the last quarter. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $25,000. Waterfront Wealth Inc. increased its position in Jazz Pharmaceuticals by 1.4% during the fourth quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company's stock worth $1,191,000 after purchasing an additional 137 shares during the last quarter. Finally, Convergence Investment Partners LLC acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at $1,033,000. Hedge funds and other institutional investors own 89.14% of the company's stock.

Remove Ads

Jazz Pharmaceuticals Stock Up 1.7 %

NASDAQ JAZZ traded up $2.36 during trading hours on Friday, reaching $138.81. 1,226,524 shares of the company traded hands, compared to its average volume of 763,946. The company has a 50 day moving average of $127.85 and a two-hundred day moving average of $119.83. The stock has a market capitalization of $8.43 billion, a PE ratio of 19.55, a PEG ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 4,813 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the sale, the chief accounting officer now owns 8,237 shares of the company's stock, valued at $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 18,113 shares of company stock valued at $2,551,834. Insiders own 4.20% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on JAZZ shares. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday, November 18th. Needham & Company LLC reiterated a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and raised their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price target for the stock from $145.00 to $179.00 in a research report on Friday. Finally, Barclays reissued an "overweight" rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $189.40.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.